543 related articles for article (PubMed ID: 25318595)
21. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
Butt AQ; Mills KH
Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
[TBL] [Abstract][Full Text] [Related]
22. Adjuvants and delivery systems for antifungal vaccines: current state and future developments.
Portuondo DL; Ferreira LS; Urbaczek AC; Batista-Duharte A; Carlos IZ
Med Mycol; 2015 Jan; 53(1):69-89. PubMed ID: 25362733
[TBL] [Abstract][Full Text] [Related]
23. Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy.
Kraynyak KA; Bodles-Brakhop A; Bagarazzi M
Curr Top Microbiol Immunol; 2017; 405():55-78. PubMed ID: 25682101
[TBL] [Abstract][Full Text] [Related]
24. Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines.
Castro-Díaz N; Salaun B; Perret R; Sierro S; Romero JF; Fernández JA; Rubio-Moraga A; Romero P
Vaccine; 2012 Jan; 30(2):388-97. PubMed ID: 22079266
[TBL] [Abstract][Full Text] [Related]
25. Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
Obeid J; Hu Y; Slingluff CL
Semin Oncol; 2015 Aug; 42(4):549-61. PubMed ID: 26320060
[TBL] [Abstract][Full Text] [Related]
26. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
Speiser DE; Romero P
Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
[TBL] [Abstract][Full Text] [Related]
27. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():615240. PubMed ID: 33679703
[TBL] [Abstract][Full Text] [Related]
28. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
[TBL] [Abstract][Full Text] [Related]
29. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy.
Dredge K; Marriott JB; Todryk SM; Dalgleish AG
Cancer Immunol Immunother; 2002 Nov; 51(10):521-31. PubMed ID: 12384803
[TBL] [Abstract][Full Text] [Related]
30. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
31. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
Ikeda H; Shiku H
Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
[TBL] [Abstract][Full Text] [Related]
32. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
H Yi D; Appel S
Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
[TBL] [Abstract][Full Text] [Related]
33. Advances in strategies and methodologies in cancer immunotherapy.
Lam SS; Zhou F; Hode T; Nordquist RE; Alleruzzo L; Raker J; Chen WR
Discov Med; 2015 Apr; 19(105):293-301. PubMed ID: 25977192
[TBL] [Abstract][Full Text] [Related]
34. The application of exosomes as a nanoscale cancer vaccine.
Tan A; De La Peña H; Seifalian AM
Int J Nanomedicine; 2010 Nov; 5():889-900. PubMed ID: 21116329
[TBL] [Abstract][Full Text] [Related]
35. Interleukin‑15: a potent adjuvant enhancing the efficacy of an autologous whole‑cell tumor vaccine against Lewis lung carcinoma.
Chen X; Ni J; Meng H; Li D; Wei Y; Luo Y; Wu Y
Mol Med Rep; 2014 Oct; 10(4):1828-34. PubMed ID: 25109355
[TBL] [Abstract][Full Text] [Related]
36. Recent progress in adjuvant discovery for peptide-based subunit vaccines.
Azmi F; Ahmad Fuaad AA; Skwarczynski M; Toth I
Hum Vaccin Immunother; 2014; 10(3):778-96. PubMed ID: 24300669
[TBL] [Abstract][Full Text] [Related]
37. [Vaccination strategies for solid tumors--fundamentals, limitations, and recent results].
Atanackovic D
Ther Umsch; 2004 Jun; 61(6):389-96. PubMed ID: 15253165
[TBL] [Abstract][Full Text] [Related]
38. Personalized cancer vaccines: adjuvants are important, too.
Gouttefangeas C; Rammensee HG
Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
[TBL] [Abstract][Full Text] [Related]
39. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
40. Exploiting dendritic cells in the development of cancer vaccines.
Bracci L; Capone I; Moschella F; Proietti E; Belardelli F
Expert Rev Vaccines; 2013 Oct; 12(10):1195-210. PubMed ID: 24090117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
